Breast Cancer
Conference Coverage
Data underscore the importance of lifestyle interventions in breast cancer patients
SAN ANTONIO – Data support lifestyle interventions in women with breast cancer; jury is still out on the effects of interventions on disease...
Conference Coverage
Extended AI therapy reduces breast cancer recurrence risk, ups fracture risk
SAN ANTONIO – A meta-analysis shows reduced breast cancer recurrence with extended AI therapy, but underscores need...
Conference Coverage
Oxybutynin rapidly quells hot flashes
SAN ANTONIO - Oxybutynin reduced hot flash scores by at least two-thirds, improved measures of quality of life, and was safe and well tolerated in...
Conference Coverage
Partial- and whole-breast irradiation very close in efficacy
SAN ANTONIO – A phase 3 trial among women who had undergone lumpectomy could not refute the hypothesis that PBI was inferior to WBI, but the...
Conference Coverage
CTC counts signal treatment choice in ER-positive/HER2-negative metastatic breast cancer
SAN ANTONIO – Circulating tumor cell counts rival clinician choice for determining whether to prescribe hormonal therapy or chemotherapy,...
Conference Coverage
AMAROS: Radiation has edge for axillary treatment
SAN ANTONIO – In patients with a positive sentinel node, axillary radiation has similar efficacy to axillary lymph node dissection and less...
Conference Coverage
Dr. Ingrid A. Mayer on neoadjuvant endocrine therapy: The times are changing
SAN ANTONIO – More phase 2 neoadjuvant endocrine therapy breast cancer trials are needed to inform design of phase 3...
Conference Coverage
DTCs in marrow herald worse outcomes for early breast cancer
SAN ANTONIO – Disseminated tumor cells detected in marrow at diagnosis or primary surgery for early breast cancer are associated with worse...
Conference Coverage
Exercise during adjuvant breast cancer therapy improves CV outcomes
SAN ANTONIO – A tailored 12-month exercise program during adjuvant breast cancer treatment appears to protect...
Conference Coverage
Oxybutynin nets dramatic reduction in hot flashes
SAN ANTONIO – The 6-week reduction in a hot flash score capturing both frequency and severity was about 30% with placebo, 65% with oxybutynin 2.5...